Gastrointestinal perforation medical therapy

Jump to navigation Jump to search


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]

Gastrointestinal perforation Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating gastrointestinal perforation from other diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X-Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gastrointestinal perforation medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gastrointestinal perforation medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gastrointestinal perforation medical therapy

CDC on Gastrointestinal perforation medical therapy

Gastrointestinal perforation medical therapy in the news

Blogs on Gastrointestinal perforation medical therapy

Directions to Hospitals Treating Stomach cancer

Risk calculators and risk factors for Gastrointestinal perforation medical therapy

Overview

Initial management of the patient with gastrointestinal perforation includes intravenous fluid therapy and broad-spectrum antibiotics. Patients with intestinal perforation can have severe volume depletion. The administration of intravenous proton pump inhibitors. Electrolyte abnormalities correction especially metabolic alkalosis if fistula developed. The severity of any electrolyte abnormalities depends upon the nature and volume of material leaking from the gastrointestinal tract. Intravenous vasopressors are useful in patients who remain hypotensive despite adequate fluid resuscitation or who develop cardiogenic pulmonary edema. Norepinephrine is the first-line single agent in septic shock. The addition of a second or third agent to norepinephrine may be required.

Gastrointestinal perforation medical therapy

Antibiotics 

Broad-spectrum antibiotic therapy is initiated if the level of perforation is unknown. The following tabel shows the regimens of choice in these cases:[1]

Regimen Dose
First choice regimens
Ampicillin-sulbactam 3 g IV every six hours
Piperacillin-tazobactam 3.375 or 4.5 g IV every six hours
Ticarcillin-clavulanate 3.1 g IV every four hours
Ceftriaxone 1 g IV every 24 hours
Metronidazole 500 mg IV every eight hours
Alternative regimens
Ciprofloxacin 400 mg IV every 12 hours
Levofloxacin 500 or 750 mg IV once daily
Metronidazole 500 mg IV every eight hours
Imipenem-cilastatin 500 mg IV every six hours
Meropenem 1 g IV every eight hours
Doripenem 500 mg IV every eight hours
Ertapenem 1 g IV once daily

Intravenous fluid therapy

Dynamic measures for circulation

  • There is an evidence that dynamic measures are more accurate predictors of fluid responsiveness than static measures. These measures include:[7]
  • Respiratory changes in the vena cava
  • Radial artery pulse pressure
  • Aortic blood flow peak velocity
  • Left ventricular outflow tract velocity-time integral
  • Brachial artery blood flow velocity are considered dynamic measures of fluid responsiveness
  • Serum lactate in patients with sepsis should be assessed until the lactate value has clearly fallen.

Vasopressors

References

  1. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH (2000). "The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting". Chest. 118 (1): 146–55. PMID 10893372.
  2. ProCESS Investigators. Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA; et al. (2014). "A randomized trial of protocol-based care for early septic shock". N Engl J Med. 370 (18): 1683–93. doi:10.1056/NEJMoa1401602. PMC 4101700. PMID 24635773. Review in: Ann Intern Med. 2014 Jun 17;160(12):JC9
  3. ARISE Investigators. ANZICS Clinical Trials Group. Peake SL, Delaney A, Bailey M, Bellomo R; et al. (2014). "Goal-directed resuscitation for patients with early septic shock". N Engl J Med. 371 (16): 1496–506. doi:10.1056/NEJMoa1404380. PMID 25272316. Review in: Ann Intern Med. 2015 Mar 17;162(6):JC4
  4. Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD; et al. (2015). "Trial of early, goal-directed resuscitation for septic shock". N Engl J Med. 372 (14): 1301–11. doi:10.1056/NEJMoa1500896. PMID 25776532. Review in: Ann Intern Med. 2015 Aug 18;163(4):JC10
  5. Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M; et al. (2014). "Albumin replacement in patients with severe sepsis or septic shock". N Engl J Med. 370 (15): 1412–21. doi:10.1056/NEJMoa1305727. PMID 24635772. Review in: Ann Intern Med. 2014 Jul 15;161(2):JC6
  6. Asfar P, Schortgen F, Boisramé-Helms J, Charpentier J, Guérot E, Megarbane B; et al. (2017). "Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial". Lancet Respir Med. 5 (3): 180–190. doi:10.1016/S2213-2600(17)30046-2. PMID 28219612.
  7. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R; et al. (2017). "Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016". Intensive Care Med. 43 (3): 304–377. doi:10.1007/s00134-017-4683-6. PMID 28101605.
  8. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C; et al. (2010). "Comparison of dopamine and norepinephrine in the treatment of shock". N Engl J Med. 362 (9): 779–89. doi:10.1056/NEJMoa0907118. PMID 20200382.
  9. Marik PE, Mohedin M (1994). "The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis". JAMA. 272 (17): 1354–7. PMID 7933396.